Scientists identify potential new drug combination for children with
Combining two existing cancer drugs could offer promise for some children with an incurable childhood brain cancer, a new study suggests.
Combining two existing cancer drugs could offer promise for some children with an incurable childhood brain cancer, a new study suggests.
UW Health experts advocate for more women in leadership positions and discuss the need to cultivate diversity to reduce disparities in cancer care.
Angela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.
A clinical trial to evaluate EIS-12656 in patients with specific types of advanced solid tumors will begin following the clearance of an investigational new drug…
An abstract is unavailable.
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
David Wetter, PhD, has been honored for pioneering cancer health equity strategies, transforming research into practical solutions, and fostering vital community partnerships for underserved populations…
This video presents the 5-year off-treatment analyses from the CLL14 and MURANO studies.
Ronan J. Kelly, MD, MBA, discusses the significance of the FDA approval of trastuzumab deruxtecan for pretreated, advanced HER2-positive solid tumors.
Stephen Williams, MD, discusses the phase 3 SunRISe-2 study investigating TAR-200 plus cetrelimab in muscle-invasive bladder cancer being presented at the 2024 American Urological Association…
T-cell help in the TME enhances rituximab-mediated NK-cell viability, CD16 and CD25 expression, and antitumor response.